( MALVERN Pa. June 15 2007 /PRNewswir...)Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey,Health

MALVERN, Pa., June 15, 2007 /PRNewswire/ -- Solstice Neurosciences, Inc. today reported important results from a multicenter, forced dose escalation study of Botulinum Toxin Type B Injectable Solution (Myobloc(R)) recently presented at the 11th International Congress of The Movement Disorders Society in Istanbul, Turkey.

This was the first multicenter study to confirm patient safety and efficacy of escalating treatment doses of 10,000 Units, 12,500 Units, and 15,000 Units of Botulinum Toxin Type B in patients with cervical dystonia (CD).

The study results were presented by Eric J. Pappert, MD, who is assistant professor of neurology and director of the Parkinson's Disease and Movement Disorders Program at the University of Texas Health Science Center in San Antonio, Texas. Dr. Pappert also serves as Vice President, Medical & Scientific Affairs of Solstice Neurosciences.

"The recommended initial dose of Type B Toxin for patients with a prior history of tolerating botulinum toxin injections is 2,500 to 5,000 Units, with subsequent dosing to be optimized according to individual patient response. Pivotal clinical trials have used doses of 5,000 and 10,000 Units," said Dr. Pappert. "So, these data provide important insights for understanding how patients respond to higher doses. The results will also help guide the design of future studies."

    Highlights from the open-label study included the following:


    -- 145 Subjects (95% Caucasian, 65% Female, Mean Age=53.1 years)

    -- Previous experience with neurotoxins

       -- Resistant to Type A (n=32; 22%)

       -- Responsive to Type A (n=113; 78%)

    -- Treatment: 3 escalating doses (10,000 Units, 12,500 Units, 15,000

       Units)

    -- Measurement intervals: baseline, 2 weeks, every 4 weeks

    -- Effectiveness measurements:

       -- Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total

          Score (Torticollis Severity, Disability, Pain)

       --
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the
Clinical Trial of MediGenes Cancer-Killing Virus in Press
Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes
Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel
Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase
III Clinical Trial of Vekacia in Children Suffering From Vernal
Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International
Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for
the Treatment of Obesity at the American Diabetes Association 67th
Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its
Ghrelin Antagonist Program at the American Diabetes Associations
Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of
Improved Glycemic Control and Significant Reductions of
LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the
Control of Influenza Conference